- Home
- OTLK vs MYND Comparison
OTLK vs MYND Comparison
Compare OTLK & MYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- MYND
- Stock Information
- Founded
- OTLK 2010
- MYND 1998
- Country
- OTLK United States
- MYND United States
- Employees
- OTLK N/A
- MYND N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- MYND Other Consumer Services
- Sector
- OTLK Health Care
- MYND Real Estate
- Exchange
- OTLK Nasdaq
- MYND Nasdaq
- Market Cap
- OTLK 48.3M
- MYND 42.3M
- IPO Year
- OTLK 2016
- MYND 2017
- Fundamental
- Price
- OTLK $1.57
- MYND $0.87
- Analyst Decision
- OTLK Strong Buy
- MYND
- Analyst Count
- OTLK 5
- MYND 0
- Target Price
- OTLK $9.60
- MYND N/A
- AVG Volume (30 Days)
- OTLK 796.7K
- MYND 13.6K
- Earning Date
- OTLK 08-13-2025
- MYND 03-26-2025
- Dividend Yield
- OTLK N/A
- MYND N/A
- EPS Growth
- OTLK N/A
- MYND N/A
- EPS
- OTLK 0.83
- MYND N/A
- Revenue
- OTLK N/A
- MYND $267,380,999.00
- Revenue This Year
- OTLK N/A
- MYND N/A
- Revenue Next Year
- OTLK $379.84
- MYND N/A
- P/E Ratio
- OTLK $1.91
- MYND N/A
- Revenue Growth
- OTLK N/A
- MYND N/A
- 52 Week Low
- OTLK $0.87
- MYND $0.61
- 52 Week High
- OTLK $9.25
- MYND $3.89
- Technical
- Relative Strength Index (RSI)
- OTLK 40.37
- MYND 48.86
- Support Level
- OTLK $1.65
- MYND $0.83
- Resistance Level
- OTLK $2.04
- MYND $0.97
- Average True Range (ATR)
- OTLK 0.12
- MYND 0.10
- MACD
- OTLK -0.03
- MYND -0.01
- Stochastic Oscillator
- OTLK 2.13
- MYND 42.11
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About MYND Mynd.ai Inc.
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more. Geographically, it operates in United States and Rest of the world.